Danaher Co. (NYSE:DHR) Stock Position Increased by Twelve Points Wealth Management LLC

Twelve Points Wealth Management LLC grew its position in Danaher Co. (NYSE:DHR) by 2.0% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 2,662 shares of the conglomerate’s stock after purchasing an additional 53 shares during the period. Twelve Points Wealth Management LLC’s holdings in Danaher were worth $740,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in the company. Vanguard Group Inc. lifted its holdings in Danaher by 7.4% in the 1st quarter. Vanguard Group Inc. now owns 60,107,030 shares of the conglomerate’s stock valued at $15,009,928,000 after acquiring an additional 4,163,657 shares during the last quarter. Swedbank AB acquired a new stake in Danaher during the first quarter valued at approximately $676,545,000. TD Asset Management Inc boosted its holdings in Danaher by 99.0% during the second quarter. TD Asset Management Inc now owns 1,358,706 shares of the conglomerate’s stock worth $339,473,000 after buying an additional 675,952 shares in the last quarter. Massachusetts Financial Services Co. MA grew its position in Danaher by 22.7% in the second quarter. Massachusetts Financial Services Co. MA now owns 3,047,728 shares of the conglomerate’s stock worth $761,475,000 after buying an additional 563,546 shares during the last quarter. Finally, Castle Hook Partners LP bought a new position in shares of Danaher in the first quarter valued at $98,913,000. Institutional investors and hedge funds own 79.05% of the company’s stock.

Insiders Place Their Bets

In other news, SVP Brian W. Ellis sold 9,600 shares of the stock in a transaction that occurred on Thursday, July 25th. The stock was sold at an average price of $275.16, for a total value of $2,641,536.00. Following the completion of the sale, the senior vice president now directly owns 20,230 shares of the company’s stock, valued at approximately $5,566,486.80. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, SVP Georgeann Couchara sold 952 shares of the company’s stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $268.37, for a total value of $255,488.24. Following the sale, the senior vice president now owns 4,212 shares of the company’s stock, valued at $1,130,374.44. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, SVP Brian W. Ellis sold 9,600 shares of Danaher stock in a transaction that occurred on Thursday, July 25th. The shares were sold at an average price of $275.16, for a total value of $2,641,536.00. Following the sale, the senior vice president now directly owns 20,230 shares in the company, valued at $5,566,486.80. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 39,659 shares of company stock valued at $11,042,433 in the last three months. Company insiders own 11.10% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the company. TD Cowen raised their price objective on Danaher from $290.00 to $310.00 and gave the stock a “buy” rating in a research note on Wednesday, July 24th. Wells Fargo & Company began coverage on Danaher in a research report on Tuesday, August 27th. They issued an “equal weight” rating and a $280.00 price target for the company. Bank of America boosted their price objective on Danaher from $270.00 to $275.00 and gave the stock a “neutral” rating in a report on Wednesday, July 24th. Royal Bank of Canada restated an “outperform” rating and set a $300.00 price target on shares of Danaher in a report on Friday, September 6th. Finally, Stephens assumed coverage on shares of Danaher in a research note on Tuesday, October 1st. They set an “overweight” rating and a $315.00 target price on the stock. Seven analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. According to data from MarketBeat.com, Danaher presently has an average rating of “Moderate Buy” and a consensus target price of $282.12.

Danaher Stock Down 1.7 %

Shares of DHR stock opened at $267.99 on Thursday. The company has a market capitalization of $198.50 billion, a price-to-earnings ratio of 45.42, a PEG ratio of 4.49 and a beta of 0.83. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.04 and a current ratio of 1.43. The stock’s 50 day simple moving average is $270.53 and its 200 day simple moving average is $259.65. Danaher Co. has a twelve month low of $182.09 and a twelve month high of $281.70.

Danaher (NYSE:DHR) last posted its quarterly earnings data on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.57 by $0.15. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The business had revenue of $5.74 billion during the quarter, compared to the consensus estimate of $5.59 billion. During the same period in the prior year, the firm earned $2.05 EPS. Danaher’s quarterly revenue was down 2.9% compared to the same quarter last year. As a group, research analysts predict that Danaher Co. will post 7.59 EPS for the current year.

Danaher Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 25th. Shareholders of record on Friday, September 27th will be issued a $0.27 dividend. This represents a $1.08 dividend on an annualized basis and a yield of 0.40%. The ex-dividend date of this dividend is Friday, September 27th. Danaher’s dividend payout ratio (DPR) is currently 18.31%.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.